Caimi PF et al. Long-term responses with loncastuximab tesirine: Updated results from LOTIS-2, the pivotal phase 2 study in patients with relapsed/refractory diffuse large B-cell lymphoma. EHA 2023;Abstract P1132.
Cohen JB et al. Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: Safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study. ASH 2023;Abstract 981.
Duell J et al. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: Final 5-year efficacy and safety findings in the phase II L-MIND study. Haematologica 2024;109(2):553-66. Abstract
Goy A et al. Outcomes of patients with relapsed/refractory mantle cell lymphoma (R/R MCL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-2 and ZUMA-18, an expanded access study. ASH 2023;Abstract 106.
Hawkes EA et al. A window study of acalabrutinib & rituximab, followed by chemotherapy & autograft (ASCT) in fit patients with treatment naïve mantle cell lymphoma (MCL): First report of the investigator-initiated Australasian Leukaemia & Lymphoma Group NHL33 ‘Wamm’ trial. ASH 2023;Abstract 735.
Hutchings M et al. Glofitamab monotherapy in relapsed or refractory large B-cell lymphoma: Extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume. ASH 2023;Abstract 433.
Jain P et al. Acalabrutinib with rituximab as first-line therapy for older patients with mantle cell lymphoma — A phase II clinical trial. ASH 2023;Abstract 3036.
Jurczak W et al. Longer follow-up from the pivotal EPCORE NHL-1 trial reaffirms subcutaneous epcoritamab induces deep, durable complete remissions in patients with relapsed/refractory large B-cell lymphoma. EHA 2023;Abstract P1118.
Morschhauser F et al. Deciphering the clinical benefit of Pola-R-CHP versus R-CHOP in different genetic subtypes beyond cell of origin in the POLARIX study. ASH 2023;Abstract 3000.
Morschhauser F et al. TRANSCEND FL: Phase 2 study primary analysis of lisocabtagene maraleucel as second-line therapy in patients with high-risk relapsed or refractory follicular lymphoma. ASH 2023;Abstract 602.
Neelapu SS et al. Axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: 4-year follow-up from the phase 2 ZUMA-5 trial. ASH 2023;Abstract 4868.
Rutherford SC et al. Nivolumab-AVD is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged ≥60 years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826. ASH 2023;Abstract 181.
Schuster SJ et al. Clinical outcomes of patients with relapsed/refractory follicular lymphoma treated with tisagenlecleucel: Phase 2 Elara 3-year follow-up. ASH 2023;Abstract 601.
Schuster SJ et al. Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal phase II study. ASH 2023;Abstract 603.
Stepan L et al. Circulating tumor DNA dynamics as early outcome predictors for lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma from the Phase 3 TRANSFORM study. ASH 2023;Abstract 225.
Wang M et al. Ibrutinib combined with venetoclax in patients with relapsed/refractory mantle cell lymphoma: Primary analysis results from the randomized phase 3 Sympatico study. ASH 2023;Abstract LBA-2.
Wang ML et al. Patient-reported outcomes from the MCL cohort of the phase 1, seamless design TRANSCEND NHL 001 study of lisocabtagene maraleucel in patients with R/R B-cell NHL. ASH 2023;Abstract 667.
Westin J et al. Smart Stop: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy for the treatment of newly diagnosed diffuse large B-cell lymphoma. ASH 2023;Abstract 856.
Westin JR et al. Primary overall survival analysis of the phase 3 randomized ZUMA7 study of axicabtagene ciloleucel versus standardofcare therapy in relapsed/refractory large B-cell lymphoma. ASCO 2023;Abstract LBA107.